Intelligence · Drug directory

Withdrawn Drug Applications

Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.

Quick answer

Withdrawn applications: NovaPharmaNews tracks 229 pharmaceutical drugs in this segment. Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.

229 drugs · Withdrawn · by data quality · Page 10 of 10

  1. tesamorelin

    EGRIFTA

    EMA: application withdrawn · NMPA: clinical trials

  2. thrombin alfa

    RECOTHROM

    EMA: application withdrawn

  3. tilmanocept

    LYMPHOSEEK

    EMA: withdrawn

    V09IA09
  4. tixagevimab

    EVUSHELD

    EMA: withdrawn

  5. trastuzumab duocarmazine

    JIVADCO

    EMA: application withdrawn

  6. trenonacog alfa

    IXINITY

    EMA: application withdrawn

    B02BD12
  7. troriluzole

    DAZLUMA

    EMA: application withdrawn

    N07XX
  8. trovafloxacin

    TURVEL

    EMA: withdrawn

    J01MA13
  9. ulipristal

    ESMYA

    EMA: withdrawn

    G03XB02
  10. vorapaxar

    ZONTIVITY

    EMA: withdrawn

    B01
  11. vosaroxin

    QINPREZO

    EMA: application withdrawn

    L01
  12. votumumab

    HUMASPECT

    EMA: withdrawn

    V09IX
  13. ximelagatran

    XIMELAGATRAN 36 MG FILM COATED TABLETS

    EMA: application withdrawn

Frequently asked questions

How many withdrawn drugs are listed?

229 drug profiles match this regulatory segment in our published index.

Where does approval data come from?

Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.